STERIS plc (STE) Stock Analysis

Founded in 1985 and headquartered in Mentor, Ohio, STERIS plc operates in the healthcare sector as a medical device and infection prevention specialist. The business runs across three core segments: Healthcare, Applied Sterilization Technologies, and Life Sciences. They manufacture and service essential hospital hardware like sterilizers, surgical tables, and automated endoscope reprocessors, alongside consumable cleaning chemistries and steam generators. Their primary customer base includes hospital surgical suites, outpatient centers, and commercial biopharmaceutical manufacturing facilities across the United States, Ireland, and global markets.

STERIS is the clear market leader in contract sterilization and surgical infection control. The Healthcare segment delivers roughly 70% of total revenue, while Applied Sterilization Technologies accounts for approximately 20%. Their moat comes from massive regulatory switching costs and sticky, recurring revenue streams from maintenance agreements and proprietary chemistries. They face targeted competition from specialist rival Sotera Health in contract sterilization, as well as broader medtech players like Getinge and Stryker.

With a market valuation near $21.9 billion, STERIS is steadily growing by tilting its revenue mix toward high-margin recurring services rather than one-off hardware sales. Strategic tuck-in acquisitions, such as Cantel Medical and Key Surgical, have cemented their dominance in endoscope processing and procedural workflows. While lumpy hospital capital budgets present a recurring risk to equipment shipments, over half of their business remains protected by non-discretionary repair, testing, and sterilization contracts.